Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.88 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 3/20 | 0.35 |
| ▸ | GABRD | O14764 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL229819 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL10710877 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL2017287 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL229818 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL17113862 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL3486854 | 1.00 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL27597271 | 0.95 | SLC7A5 (0.79) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL1813972 | 0.94 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL8516 | 0.94 | — | — | |
| Valine SCHEMBL288203 | 0.94 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004009625-A2 | PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES | THE UNIVERSITY OF LANCASTER (GB) | 2004-01-29 | — | — | WO | claimed |
| US-20240165257-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-05-23 | — | — | US | disclosed |
| WO-2024094688-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2024-05-10 | — | — | WO | disclosed |
| US-20220047644-A1 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | FIBROBIOLOGICS, LLC | 2022-02-17 | — | — | US | disclosed |
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | US | disclosed |
| EP-1879886-B1 | Inhibitors of mitotic kinesins and their therapeutical use | ARRAY BIOPHARMA INC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
| US-8268871-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7795282-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1879886-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006119146-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247178-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-11-02 | — | — | US | disclosed |
| EP-1493454-A9 | BIOMATERIALS FOR NERVE RECONSTRUCTION AND PROCESS FOR PRODUCING THE SAME | Japan Science and Technology Agency (JP) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004009625-A2 | PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES | THE UNIVERSITY OF LANCASTER (GB) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SLC7A5 4056/4885SLC1A3 3325/4885SLC1A2 3522/4885 |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SLC7A5 4194/4885SLC1A3 2870/4885SLC1A2 2687/4885 |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SLC7A5 4194/4885SLC1A3 2870/4885SLC1A2 2687/4885 |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF2C, KIFC1 | SLC7A5 4056/4885SLC1A3 3325/4885SLC1A2 3522/4885 |
| US-20060247178-A1 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF2C, KIFC1 | SLC7A5 4056/4885SLC1A3 3325/4885SLC1A2 3522/4885 |
| US-20240165257-A1 | ANTI-GUCY2C ANTIBODY AND USES THEREOF | GUCY1B2, MTX2, GUCY1A2 | SLC7A5 1909/4885SLC1A3 1666/4885SLC1A2 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.